Consultation record

Submissions accepted in part — page 2

Part of the submission is accepted and part is not. The secretariat response states which part is which and on what ground the remainder was declined.

Submissions

390 documents · page 2 of 13

Table 1. Submissions with this disposition, on this page.

Reference	Consultation	Respondent	Point raised
DRAFT-WEIGHT-REGAI/012	Draft synthesis: weight change after discontinuation of an incretin…	Dr Matthias Wintringham industry	A sponsor trial meeting the eligibility criteria was excluded
DRAFT-NETWORK-TRAN/002	Draft methodological review: transitivity in the incretin network	Dr Vasilisa Immelmann	Regulatory assessment documents were not searched
DRAFT-NETWORK-TRAN/003	Draft methodological review: transitivity in the incretin network	Dr Yaa Kettlewell	Statistical heterogeneity is treated as though it measured clinical heterogeneity
DRAFT-NETWORK-TRAN/004	Draft methodological review: transitivity in the incretin network	Eamon Sandringham-Adu	The review protocol is described but its registration record is not linked
DRAFT-CONFLICTS-PO/007	Draft conflicts-of-interest policy	Georgiana Zimmerthal	The materiality threshold for a declarable holding is set too high
DRAFT-CONFLICTS-PO/008	Draft conflicts-of-interest policy	Ignatius Erlingsson	A four-week window is too short for a respondent without institutional support
DRAFT-CONFLICTS-PO/009	Draft conflicts-of-interest policy	Dr Rurik Haverkamp-Diallo	Funding should not be accepted from any party the Institute assesses
DRAFT-FUNDING-POLI/005	Draft funding and sponsorship policy	Ivo Mountstephen	References should carry a persistent identifier for every cited source
DRAFT-FUNDING-POLI/007	Draft funding and sponsorship policy	Ignatius Erlingsson	A four-week window is too short for a respondent without institutional support
DRAFT-CITATION-POL/008	Draft citation policy	Dr Vasilisa Sandringham-Adu	The materiality threshold for a declarable holding is set too high
DRAFT-PROGRAMME-RE/002	Draft policy: labelling of Institute-constructed programme records	Ms Rhiannon Okoye-Vandergraaf	The document is unreadable without specialist training
DRAFT-PROGRAMME-RE/006	Draft policy: labelling of Institute-constructed programme records	Kamila Ubertini	A four-week window is too short for a respondent without institutional support
DRAFT-PROGRAMME-RE/009	Draft policy: labelling of Institute-constructed programme records	Dr Wojciech Kaltenbach-Mensah	The secretariat answers submissions and is not itself named
DRAFT-PROGRAMME-RE/011	Draft policy: labelling of Institute-constructed programme records	Dr Vasilisa Immelmann	A party criticised in an assessment should have a right of reply
DRAFT-PROGRAMME-RE/012	Draft policy: labelling of Institute-constructed programme records	Dr Emiliana Ollerenshaw	Funding should not be accepted from any party the Institute assesses
DRAFT-ENDOTOXIN-ST/002	Draft standard: bacterial endotoxin testing of peptide presentations	Dr Quentin Zimmerthal	Nothing in the standard addresses transfer of the method between laboratories
DRAFT-ENDOTOXIN-ST/006	Draft standard: bacterial endotoxin testing of peptide presentations	Bertrand Ollerenshaw industry	The additional determinations required would materially increase release testing cost
DRAFT-ENDOTOXIN-ST/007	Draft standard: bacterial endotoxin testing of peptide presentations	Thaddeus Isaksen-Balogun	Point estimates are given without an interval
DRAFT-ENDOTOXIN-ST/008	Draft standard: bacterial endotoxin testing of peptide presentations	Dr Jolanta Uttridge	Nothing addresses the container the material was held in
DRAFT-ENDOTOXIN-ST/012	Draft standard: bacterial endotoxin testing of peptide presentations	Dr Hortensia Hollingworth	Nothing requires a laboratory to demonstrate ongoing performance
DRAFT-ANALYTICAL-S/003	Draft scope of the analytical and methodological standards series	Eamon Sandringham-Adu	References should carry a persistent identifier for every cited source
DRAFT-ANALYTICAL-S/004	Draft scope of the analytical and methodological standards series	Amara Vandergraaf	Defined terms are defined in a glossary the reader has to know exists
DRAFT-ANALYTICAL-S/009	Draft scope of the analytical and methodological standards series	Dr Marisol Dunmore-Ekpo	An index organised by certainty invites comparison between ratings that are not comparable
DRAFT-GLP1-OBESITY/002	Draft synthesis: glucagon-like peptide-1 receptor agonists for weight…	Dr Yaa Kettlewell	The axis of the forest plot exaggerates a small difference
DRAFT-GLP1-OBESITY/005	Draft synthesis: glucagon-like peptide-1 receptor agonists for weight…	Ms Rhiannon Okoye-Vandergraaf	The document is unreadable without specialist training
DRAFT-GLP1-OBESITY/007	Draft synthesis: glucagon-like peptide-1 receptor agonists for weight…	Professor Bartolomeu Nkosi-Lindegaard	Regulatory assessment documents were not searched
DRAFT-GLP1-OBESITY/008	Draft synthesis: glucagon-like peptide-1 receptor agonists for weight…	Dr Liesbeth Nordhagen industry	A sponsor trial meeting the eligibility criteria was excluded
DRAFT-GLP1-OBESITY/009	Draft synthesis: glucagon-like peptide-1 receptor agonists for weight…	Quentin Whitmarsh-Obi	The review protocol is described but its registration record is not linked
DRAFT-GLP1-OBESITY/013	Draft synthesis: glucagon-like peptide-1 receptor agonists for weight…	Dr Oisín Rautavaara	The choice of effect measure is not justified and changes the appearance of the result
DRAFT-LEAN-MASS-SC/001	Draft scoping review: change in lean mass during pharmacologically…	Ms Rhiannon Okoye-Vandergraaf	Patient-reported outcomes are collected by the trials and not reported by the review

page 2 of 13